Envoy Medical Seeks Shareholder Approval for Reverse Stock Split to Regain Nasdaq Compliance

summarizeSummary

Envoy Medical is seeking shareholder approval for a reverse stock split to lift its share price above $1.00 and avoid Nasdaq delisting, with a special meeting set for October 12, 2026.

check_boxKey Events · Corporate Governance and Compliance · COCH

• Reverse Stock Split Proposal

  Board seeks approval to effect a reverse stock split at a ratio of 1-for-5 to 1-for-25, with discretion to implement before December 31, 2026.

• Nasdaq Compliance Deadline

  Company must regain compliance with the $1.00 minimum bid price rule by November 16, 2026, or face delisting proceedings.

• Special Meeting Scheduled

  Stockholders will vote on the proposal at a special meeting on October 12, 2026, with a record date of August 19, 2026.

• Board Recommendation

  The Board unanimously recommends voting FOR the reverse stock split and the adjournment proposal.

auto_awesomeAnalysis · COCH · Industrial Applications And Services

Envoy Medical is asking shareholders to approve a reverse stock split at a ratio between 1-for-5 and 1-for-25, with the Board having discretion to implement it before December 31, 2026. The company's stock trades at $0.74, below the $1.00 Nasdaq minimum bid price requirement, and it faces delisting if it cannot regain compliance by November 16, 2026. The reverse split is intended to boost the share price above $1.00 and maintain the Nasdaq listing, which is critical for access to capital markets and future financing. However, the proxy statement warns that the split may not sustain a higher price and could lead to further declines, and if the stock falls below $1.00 again within a year, the company faces immediate delisting without another compliance period.